nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—Translation Factors—EIF2AK1—pharynx cancer	0.158	0.252	CbGpPWpGaD
Sirolimus—EIF4E—lymphoid tissue—pharynx cancer	0.035	0.0934	CbGeAlD
Sirolimus—EIF4E—head—pharynx cancer	0.0282	0.0753	CbGeAlD
Sirolimus—MTOR—neck—pharynx cancer	0.0258	0.069	CbGeAlD
Sirolimus—FGF2—trachea—pharynx cancer	0.0245	0.0654	CbGeAlD
Sirolimus—FKBP1A—neck—pharynx cancer	0.0232	0.062	CbGeAlD
Sirolimus—MTOR—brainstem—pharynx cancer	0.0197	0.0527	CbGeAlD
Sirolimus—FGF2—spinal cord—pharynx cancer	0.0193	0.0516	CbGeAlD
Sirolimus—CYP3A4—Fatty Acid Omega Oxidation—ADH7—pharynx cancer	0.0181	0.029	CbGpPWpGaD
Sirolimus—MTOR—epithelium—pharynx cancer	0.0176	0.0469	CbGeAlD
Sirolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—pharynx cancer	0.0162	0.0259	CbGpPWpGaD
Sirolimus—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—pharynx cancer	0.0159	0.0254	CbGpPWpGaD
Sirolimus—FKBP1A—epithelium—pharynx cancer	0.0158	0.0422	CbGeAlD
Sirolimus—SLC47A1—brainstem—pharynx cancer	0.0153	0.0407	CbGeAlD
Sirolimus—CYP3A7—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.0152	0.0243	CbGpPWpGaD
Sirolimus—FKBP1A—trachea—pharynx cancer	0.014	0.0373	CbGeAlD
Sirolimus—MTOR—lymphoid tissue—pharynx cancer	0.0135	0.0361	CbGeAlD
Sirolimus—CYP3A7—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.0133	0.0213	CbGpPWpGaD
Sirolimus—MTOR—spinal cord—pharynx cancer	0.0123	0.0328	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—pharynx cancer	0.0122	0.0325	CbGeAlD
Sirolimus—FGF2—lymph node—pharynx cancer	0.012	0.0321	CbGeAlD
Sirolimus—EIF4E—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—pharynx cancer	0.0117	0.0187	CbGpPWpGaD
Sirolimus—EIF4E—Signaling mediated by p38-alpha and p38-beta—TP53—pharynx cancer	0.0111	0.0178	CbGpPWpGaD
Sirolimus—FKBP1A—spinal cord—pharynx cancer	0.011	0.0295	CbGeAlD
Sirolimus—CYP3A5—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.011	0.0176	CbGpPWpGaD
Sirolimus—MTOR—head—pharynx cancer	0.0109	0.0291	CbGeAlD
Sirolimus—FKBP1A—head—pharynx cancer	0.00981	0.0262	CbGeAlD
Sirolimus—CYP3A5—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.00963	0.0154	CbGpPWpGaD
Sirolimus—SLC47A1—spinal cord—pharynx cancer	0.00949	0.0253	CbGeAlD
Sirolimus—EIF4E—Leptin signaling pathway—CCND1—pharynx cancer	0.00918	0.0147	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—CNDP2—pharynx cancer	0.00892	0.0143	CbGpPWpGaD
Sirolimus—SLC47A1—head—pharynx cancer	0.00843	0.0225	CbGeAlD
Sirolimus—CYP3A7—Biological oxidations—ADH7—pharynx cancer	0.00807	0.0129	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP8—pharynx cancer	0.00797	0.0127	CbGpPWpGaD
Sirolimus—MTOR—lymph node—pharynx cancer	0.00764	0.0204	CbGeAlD
Sirolimus—CYP3A7—Biological oxidations—ADH1B—pharynx cancer	0.00708	0.0113	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—B4GALT5—pharynx cancer	0.00689	0.011	CbGpPWpGaD
Sirolimus—FKBP1A—lymph node—pharynx cancer	0.00687	0.0183	CbGeAlD
Sirolimus—CYP3A5—Biological oxidations—CNDP2—pharynx cancer	0.00645	0.0103	CbGpPWpGaD
Sirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—pharynx cancer	0.00618	0.00989	CbGpPWpGaD
Sirolimus—SLC47A1—lymph node—pharynx cancer	0.00591	0.0158	CbGeAlD
Sirolimus—CYP3A5—Biological oxidations—ADH7—pharynx cancer	0.00583	0.00933	CbGpPWpGaD
Sirolimus—EIF4E—Validated targets of C-MYC transcriptional activation—TP53—pharynx cancer	0.0058	0.00928	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—CD79A—pharynx cancer	0.00572	0.00915	CbGpPWpGaD
Sirolimus—FGF2—Neural Crest Differentiation—CDH1—pharynx cancer	0.00539	0.00863	CbGpPWpGaD
Sirolimus—MTOR—CDC42 signaling events—CDH1—pharynx cancer	0.00537	0.00859	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—ADH1B—pharynx cancer	0.00511	0.00818	CbGpPWpGaD
Sirolimus—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.0051	0.00816	CbGpPWpGaD
Sirolimus—MTOR—Wnt Signaling Pathway Netpath—CCND1—pharynx cancer	0.00508	0.00812	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—CCND1—pharynx cancer	0.00492	0.00788	CbGpPWpGaD
Sirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—pharynx cancer	0.00482	0.00772	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—CCND1—pharynx cancer	0.00469	0.00749	CbGpPWpGaD
Sirolimus—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.00448	0.00716	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—CD79A—pharynx cancer	0.00425	0.00679	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—CCND1—pharynx cancer	0.0041	0.00655	CbGpPWpGaD
Sirolimus—MTOR—LKB1 signaling events—TP53—pharynx cancer	0.00389	0.00623	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—EGFR—pharynx cancer	0.00386	0.00618	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—CCND1—pharynx cancer	0.00379	0.00606	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—EGFR—pharynx cancer	0.00368	0.00588	CbGpPWpGaD
Sirolimus—ABCB1—epithelium—pharynx cancer	0.00366	0.00976	CbGeAlD
Sirolimus—FGF2—Constitutive PI3K/AKT Signaling in Cancer—EGFR—pharynx cancer	0.00359	0.00574	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—TP53—pharynx cancer	0.00324	0.00519	CbGpPWpGaD
Sirolimus—ABCB1—trachea—pharynx cancer	0.00323	0.00863	CbGeAlD
Sirolimus—FGF2—PI-3K cascade—EGFR—pharynx cancer	0.00323	0.00517	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—EGFR—pharynx cancer	0.00321	0.00514	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.00319	0.0051	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—EGFR—pharynx cancer	0.00315	0.00505	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—EGFR—pharynx cancer	0.00313	0.00501	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—B4GALT5—pharynx cancer	0.00311	0.00498	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TP53—pharynx cancer	0.00309	0.00494	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—pharynx cancer	0.00306	0.00489	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CNDP2—pharynx cancer	0.003	0.0048	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CDH1—pharynx cancer	0.0029	0.00464	CbGpPWpGaD
Sirolimus—ABCB1—lymphoid tissue—pharynx cancer	0.00282	0.00752	CbGeAlD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.0028	0.00447	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—ADH7—pharynx cancer	0.00271	0.00434	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TP53—pharynx cancer	0.00267	0.00426	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—pharynx cancer	0.00266	0.00426	CbGpPWpGaD
Sirolimus—ABCB1—spinal cord—pharynx cancer	0.00255	0.00682	CbGeAlD
Sirolimus—EIF4E—Immune System—CD79A—pharynx cancer	0.00252	0.00403	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—CDH1—pharynx cancer	0.0025	0.004	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.0025	0.004	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—EGFR—pharynx cancer	0.00242	0.00386	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.00242	0.00386	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—EGFR—pharynx cancer	0.0024	0.00384	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—ADH1B—pharynx cancer	0.00238	0.0038	CbGpPWpGaD
Sirolimus—FGF2—Disease—B4GALT5—pharynx cancer	0.00236	0.00377	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—EGFR—pharynx cancer	0.00234	0.00374	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—EGFR—pharynx cancer	0.00232	0.00372	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.00231	0.0037	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.00231	0.0037	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD79A—pharynx cancer	0.00231	0.00369	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—EGFR—pharynx cancer	0.00227	0.00364	CbGpPWpGaD
Sirolimus—ABCB1—head—pharynx cancer	0.00227	0.00606	CbGeAlD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—pharynx cancer	0.00227	0.00363	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—EGFR—pharynx cancer	0.00227	0.00363	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—EGFR—pharynx cancer	0.00217	0.00347	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CCND1—pharynx cancer	0.00216	0.00346	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—EGFR—pharynx cancer	0.00216	0.00346	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—EGFR—pharynx cancer	0.00215	0.00344	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—EGFR—pharynx cancer	0.00214	0.00342	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00211	0.00337	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.0021	0.00336	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—EGFR—pharynx cancer	0.00201	0.00322	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—EGFR—pharynx cancer	0.00201	0.00322	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.00201	0.00322	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—EGFR—pharynx cancer	0.002	0.00319	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.00198	0.00316	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—EGFR—pharynx cancer	0.00197	0.00315	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—pharynx cancer	0.00191	0.00305	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.0019	0.00303	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—EGFR—pharynx cancer	0.00186	0.00298	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—EGFR—pharynx cancer	0.00179	0.00287	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00178	0.00285	CbGpPWpGaD
Sirolimus—MTOR—Disease—B4GALT5—pharynx cancer	0.00175	0.0028	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.00172	0.00274	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD79A—pharynx cancer	0.00171	0.00274	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.0017	0.00271	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—EGFR—pharynx cancer	0.00169	0.0027	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CNDP2—pharynx cancer	0.00166	0.00266	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—EGFR—pharynx cancer	0.00161	0.00258	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.0016	0.00257	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—pharynx cancer	0.0016	0.00257	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—pharynx cancer	0.0016	0.00255	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.00159	0.00254	CbGpPWpGaD
Sirolimus—ABCB1—lymph node—pharynx cancer	0.00159	0.00424	CbGeAlD
Sirolimus—MTOR—DAP12 signaling—EGFR—pharynx cancer	0.00159	0.00254	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00157	0.0025	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CNDP2—pharynx cancer	0.00153	0.00244	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ADH7—pharynx cancer	0.0015	0.0024	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—pharynx cancer	0.00149	0.00239	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—pharynx cancer	0.00149	0.00239	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.00149	0.00239	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—pharynx cancer	0.00148	0.00237	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.00147	0.00235	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—pharynx cancer	0.00146	0.00234	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.00143	0.00228	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CDH1—pharynx cancer	0.0014	0.00224	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD79A—pharynx cancer	0.0014	0.00224	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—pharynx cancer	0.00138	0.00221	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ADH7—pharynx cancer	0.00138	0.00221	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—pharynx cancer	0.00137	0.00219	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00132	0.00212	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ADH1B—pharynx cancer	0.00132	0.00211	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CDH1—pharynx cancer	0.00128	0.00206	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—B4GALT5—pharynx cancer	0.00126	0.00202	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ADH1B—pharynx cancer	0.00121	0.00194	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—B4GALT5—pharynx cancer	0.00116	0.00185	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CNDP2—pharynx cancer	0.0011	0.00176	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD79A—pharynx cancer	0.00104	0.00166	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—pharynx cancer	0.00102	0.00163	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADH7—pharynx cancer	0.000998	0.0016	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDH1—pharynx cancer	0.000954	0.00153	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—pharynx cancer	0.000911	0.00146	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—pharynx cancer	0.000886	0.00142	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADH1B—pharynx cancer	0.000875	0.0014	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—B4GALT5—pharynx cancer	0.000836	0.00134	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CNDP2—pharynx cancer	0.000832	0.00133	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—pharynx cancer	0.00082	0.00131	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—pharynx cancer	0.000783	0.00125	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDH1—pharynx cancer	0.000779	0.00125	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000772	0.00123	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADH7—pharynx cancer	0.000753	0.0012	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—pharynx cancer	0.000751	0.0012	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—pharynx cancer	0.000676	0.00108	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADH1B—pharynx cancer	0.00066	0.00106	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—B4GALT5—pharynx cancer	0.000631	0.00101	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000605	0.000968	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—pharynx cancer	0.000581	0.000929	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—pharynx cancer	0.000578	0.000925	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—pharynx cancer	0.000558	0.000892	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—pharynx cancer	0.000555	0.000888	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—pharynx cancer	0.00053	0.000848	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CNDP2—pharynx cancer	0.000513	0.00082	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000508	0.000813	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—pharynx cancer	0.000496	0.000793	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADH7—pharynx cancer	0.000464	0.000742	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—pharynx cancer	0.000456	0.000729	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—pharynx cancer	0.000445	0.000712	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—pharynx cancer	0.000421	0.000673	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADH1B—pharynx cancer	0.000407	0.00065	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—pharynx cancer	0.000389	0.000622	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—B4GALT5—pharynx cancer	0.000389	0.000622	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—pharynx cancer	0.000376	0.000601	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—pharynx cancer	0.000338	0.000541	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—pharynx cancer	0.000326	0.000522	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—pharynx cancer	0.000312	0.000499	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—pharynx cancer	0.000295	0.000471	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—pharynx cancer	0.000279	0.000446	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—pharynx cancer	0.000247	0.000396	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—pharynx cancer	0.000219	0.00035	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—pharynx cancer	0.000184	0.000294	CbGpPWpGaD
